500
Participants
Start Date
December 15, 2018
Primary Completion Date
November 5, 2019
Study Completion Date
November 5, 2019
Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum
"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
"LLC Medical Center Nebolit", Mytishchi
"LLC Research Medical Complex Vashe Zdorovie", Kazan'
"State Healthcare Institution Republican Clinical Neurological Center", Kazan'
"Regional State Budgetary Institution of Health Regional Clinical Hospital № 1 named after Prof. S.I. Sergeev", Khabarovsk
"Federal State Healthcare Institution Russian Scientific Center of Surgery named after academician B.V. Petrovsky", Moscow
"LLC Medicina", Moscow
"Non-state Healthcare Institution Central Clinical Hospital No. 2 named after N.A. Semashko of the JSC Russian Railways", Moscow
"LLC Clinical Diagnostic Center Avitsena", Naberezhnye Chelny
"LLC Licon Plus", Naberezhnye Chelny
"LLC Medis", Nizhny Novgorod
"JSC MEdical Center Avitsenna, group of companies Mother and Child", Novosibirsk
"LLC MRI-Expert Novosibirsk", Novosibirsk
"LLC Multidisciplinary center of modern medicine Euromed", Omsk
Federal State Healthcare Institution St. Petersburg Clinical Hospital of the Russian Academy of Sciences, Saint Petersburg
Out-patient clinic of SUE St. Petersburg Metropoliten, Saint Petersburg
"LLC MD Project 2010", Ufa
"LLC National Medical Holding Medstandart", Ufa
Volgograd State Medical University, Volgograd
"LLC Center of Evidence-Based Medicine", Yaroslavl
"State Healthcare Institution of Yaroslavl Region Clinical Hospital №8", Yaroslavl
"LLC Center for Medical Prevention and Rehabilitation treatment Kamkor", Yekaterinburg
Woerwag Pharma LLC
INDUSTRY